Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), which is a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide exhibited up to ~20% average weight loss in people who are living with obesity without Type 2 diabetes (T2D) as compared with 2.6% in the placebo arm, and up to ~17% average weight loss in people who are living with obesity with T2D in comparison to 1.4% in the placebo arm, per the efficacy estimand.

Amgen (AMGN) Announces Full Results from Part 1 of the Phase 2 study of MariTide

A pharmacist filling a prescription for a complex drug developed by the company.

Amgen Inc. (NASDAQ:AMGN) also added that weight loss had not plateaued by 52 weeks, which indicates the potential for further weight reduction. Apart from the meaningful weight loss, MariTide showcased a robust and sustained reduction in hemoglobin A1c (HbA1c) of up to 2.2% in people who have obesity and T2D. MariTide’s monthly or less frequent dosing can improve adherence and long-term weight control. This provides an opportunity to optimize health outcomes for people who have obesity, Type 2 diabetes, and related conditions, highlighted Amgen Inc. (NASDAQ:AMGN).

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.